Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Continued Petitions

Ocular Melanoma (MRI Scans) (PE1629)

Thursday 24 January 2019 Public Petitions Committee About 09:45–10:15 Petitions 84 contributions · 7 speakers

Speakers

Choose an MSP to read only their contributions

The record

84 contributions
Johann Lamont Lab The Convener · Glasgow
link

The next petition is PE1629, by Jennifer Lewis, on magnetic resonance imaging scans for ocular melanoma sufferers in Scotland. The petition calls for ocular melanoma sufferers to receive MRI scans of their liver to detect the early onset of metastatic disease of the liver.

The petitioner and Iain Galloway, from whom we have previously taken evidence, have been consistent in outlining what they consider to be the advantages of people receiving MRI scans with colour contrast, rather than a straightforward ultrasound scan. Members have a copy of the most recent submission from Iain Galloway, which expands on his concerns.

Once again, the cabinet secretary is accompanied by the chief medical officer and Elizabeth Sadler. I invite the cabinet secretary to make a brief opening statement.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Thank you very much, convener. I am grateful to the committee for the opportunity to give evidence on the petition, which I know has been open for some time.

Although ocular melanoma is a rare cancer, it is important that those with the disease are treated with equal importance as those who have more common cancers. The disease is managed through our National Services Scotland division at the national specialist Scottish ophthalmic oncology service at Gartnavel general hospital in Glasgow under the direction of two clinical oncologists, Dr Paul Cauchi and Dr Vikas Chadha. Both have advised Scottish Government ministers and officials throughout the committee’s consideration of the petition.

I understand that, when they lodged the petition, the petitioners were concerned that people with the condition in England were offered MRI liver scans, but that those in Scotland were not. I am advised that there has never been a difference between England and Scotland in that regard. However, the clinical community recognises that there is variation between NHS regions and departments across the UK in whether MRI scans are offered. The current situation across the UK, including in Scotland, is to follow the Melanoma Focus guidelines, which were approved by the National Institute for Health and Care Excellence in January 2015 and which advise that anyone with ocular melanoma should be offered six-monthly screening of the liver using non-ionising radiation. The most appropriate and commonly used imaging method in such cases is ultrasound.

My understanding is that anyone living in Scotland who is diagnosed with an ocular melanoma will initially be treated by an ophthalmology specialist at Gartnavel hospital—Dr Cauchi or Dr Chadha. Follow-up is provided under the direction of those specialists at local centres and is planned in consultation with the patient. During follow-up, those who are assessed as being at lower risk of developing metastatic disease are offered ultrasound scans, usually at their local hospital, with any abnormalities being followed up using MRI.

At UK and Scottish level, there is no clinical consensus for those at high risk. For all, imaging is undertaken. For those at high risk, additional imaging, including MRI, is undertaken as clinically indicated. Should a metastatic disease be found, care is transferred back to an oncologist specialising in that particular organ for the delivery of systemic therapy. MRI is not routinely used for all people, and the primary reason for that is patient safety. MRI delivers a dose of radiation and therefore regular imaging can in itself be a risk. The second reason is that the guidelines do not specifically state that MRI should be used and, as I said, there is no clinical consensus across the UK on the use of MRI.

To address the issue of variation across the UK, Dr Cauchi has made great efforts to convene a UK-wide group to update the guidelines and develop a consistent approach. When the chief medical officer wrote to the committee on 17 May 2017, there was intent to convene a UK-wide consensus group. However, since then, the other centres outside NHS Scotland have not been willing to engage in the process. Subsequent correspondence to the committee from officials mentions a Scottish guidelines group, which has been put together by Dr Cauchi, who is actively pursuing the development of Scottish guidelines in the absence of UK-wide consensus. Dr Cauchi has convened a group of clinical imaging and patient representatives, which I understand is looking to report by June this year. I am grateful to Dr Cauchi for pursuing that important work, and I look forward to receiving the group’s report in the summer.

I hope that the information that has been provided today will clarify to the committee that people in Scotland with ocular melanoma are recognised by the Scottish Government and NHS Scotland, which is why we have commissioned the national specialist service at Gartnavel. Anyone in Scotland with the disease can have an MRI scan if it is considered clinically appropriate and, thanks to Dr Cauchi, work is under way to try to ensure a degree of clinical consistency in the approach.

I am grateful for the opportunity to make that brief statement and I am happy to answer any questions that the committee has.

Johann Lamont Lab The Convener · Glasgow
link

Thank you. The centre of the issue, which we want to explore, is that the petitioners’ experience is that they do not have access to MRI scans. The caveat about the scans being deemed to be clinically appropriate will be the challenge for us all. You mentioned the Scottish guidelines group, which the petitioner and Iain Galloway referred to in their written submission of September 2018. Can you update us on the group? When did you say it will report by?

Johann Lamont Lab The Convener · Glasgow
link

What is the membership and who are the patient representatives? Will they include a patient with experience of what the petitioner refers to as

“the rarity, complex issues and scanning modalities for Ocular Melanoma”?

The petitioners feel that, because the condition is so rare, there is a lack of understanding and their direct experience of it would be relevant.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

I am happy to provide the committee with the names of those on the group, which is convened by Dr Cauchi. I understand that it has the relevant clinical specialisms, imaging expertise and a patient with experience of the disease.

Angus MacDonald SNP Falkirk East
link

The cabinet secretary will be aware that the petitioner and Mr Galloway have also previously highlighted concerns about the experience of ultrasonographers, particularly in terms of interpretation and identifying metastatic spread to the liver from uveal melanoma. How would you respond to those concerns?

Dr Calderwood
link

The convener has already mentioned the rarity of the condition. We know that there are around five cases of this ocular melanoma per million of the population. In Scotland, that would be around 25 people per year. If we were to look at one of the most common cancers—breast cancer—we would see that one in 12 women will develop breast cancer over their lifetime. That is 80,000 people per million.

We are looking at a disease that is really rare. Most doctors of any specialty and most general practitioners will never see a case in their experience and most of the staff dealing with people with ocular melanoma, other than at the specialist centre, will never before have seen a case. We understand that people who have the disease and have a great understanding of it themselves will find that others do not have that understanding and do not have the detailed knowledge.

It is clear when I look across the various guidelines that there is not clinical consensus on recommendations. In part, that is because of the small number of patients. Even across the UK, the number is small. Also, the research has not confirmed what the best modality of follow-up is and whether, in fact, one type of imaging is of greater value in ensuring that we detect metastatic disease early and, crucially, whether that makes any difference to survival.

We know that for 90 per cent of people with metastatic disease, it will be in the liver, so the right thing to do is to image the liver. Ultrasound imaging would, in routine practice, be the first port of call. Ultrasound is completely safe; it is non-ionising radiation, so it carries no further risks to the patient. If we are looking at a frequency of every six months, that is a very large number of scans over a person’s lifetime. There is not clinical consensus on whether ultrasound alone should be the modality or whether ultrasound, as a very safe procedure, followed by MRI, is the right thing to do. MRI in itself, with quite a significant dose of ionising radiation, carries with it risks, in particular if there are multiple scans over a patient’s lifetime.

Brian Whittle Con South Scotland
link

In his most recent submission, Mr Galloway states that, because

“Ultrasound scans are not recorded”,

the results of those scans are only open to interpretation at the time, whereas MRI scans are much clearer and are available for a second opinion because others can look at them. Do you have an opinion on Mr Galloway’s concerns?

Dr Calderwood
link

I suppose I am considering the use of ultrasound in general terms. The routine of an ultrasound scan is that still images are taken during the scan and those would be recorded and kept as part of a clinical record, so pictures would be available. Obviously, if an abnormality was found, a picture would be taken. Also, if you are looking in particular areas, metastatic disease can be seen in some areas of the liver earlier than in others. That is to do with the way that it spreads. There would then be pictures of clear areas of the liver to put in the patient’s record.

A report is written but, if a second opinion is needed, still images are always taken of ultrasounds, which form part of the patient’s record. I do not think that there would be video, because it is not a dynamic scan. In my specialty, which is obstetrics, we can take a video of the ultrasound to be saved and looked at again. However, it is not the case that there are no records after an ultrasound or that somebody cannot go back and look at images.

10:00

Brian Whittle Con South Scotland
link

I am not particularly expert in this, so I ask for clarity about what I think Mr Galloway is saying. If people are scanned every six months, are ultrasound stills comparable? Would being able to compare one six-month scan with the next be adequate to highlight any abnormality? Would an MRI scan not necessarily add any complexity?

Dr Calderwood
link

This is not my expert area, so I have been reading and taking advice from experts. I understand that the view is that, in cases where ultrasound is performed, it would pick up metastatic disease. The clinical consensus is that, if there are abnormalities or in groups of patients who are seen to be at high risk, there is not agreement across the country about whether to move directly to MRI scanning in every case. Everyone in Scotland will have direct access to ultrasound scans, and those people who are at high risk—there are various clinical criteria that will put people into a high-risk category, such as age and certain appearances of the melanoma—will have an ultrasound scan that progresses to an MRI, or an MRI scan directly.

At the moment, we do not have the evidence as to whether one approach will clinically change the outcome for people over a different approach. We do know that the significant dose of ionising radiation that would be given in the course of regular six-monthly MRIs has the potential to cause harm. Just to be clear, that harm would mean the risk of incidence of some of the blood cancers being significantly increased over a patient’s lifetime. That risk is not insignificant. A large dose of ionising radiation at very regular intervals carries that risk.

Johann Lamont Lab The Convener · Glasgow
link

One would have thought, then, that there would be a clinical consensus not to do it.

Dr Calderwood
link

It is always a balance of risk.

Johann Lamont Lab The Convener · Glasgow
link

We received a submission from Neil Pearce and Professor Christian Ottensmeier from the University of Southampton, who are cancer specialists, and they say:

“we tend to do an US first because it is cheap ... not because it is ... better”.

They also say that MRI is

“not harmful to patients.”

That seems to directly contradict your justification for not recognising, for something that is very rare, the request in the petition that we have MRI rather than ultrasound.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Convener, I think that it is an unfair characterisation of what we are saying to say that we do not recognise that. We are working on the basis that there is no clinical consensus here.

Johann Lamont Lab The Convener · Glasgow
link

With respect, Catherine Calderwood said that you recommend not using MRI because of increased risk. The evidence that we have is that it is not about risk, but about cost.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No. I am sure that Dr Calderwood is very able to speak for herself, but what she said was that there are risks associated with frequent MRI scans with regard to increased incidence of blood cancers. There are different clinical views as to whether that risk is balanced by reducing risk in terms of identifying metastatic spread into the liver with MRI. There is a balance of risk here.

I hope we all understand that, in almost every area of health and medicine, we ask our clinicians to constantly balance risks, and we work from how they balance those risks. That is precisely what Dr Cauchi is trying to resolve. He is trying to find a clinical consensus so that there can be greater consistency. However, I refute absolutely the suggestion that what lies behind that is any consideration of cost. Of course those who provided evidence to the committee are entitled to their view, but I disagree with that view. It is not about cost. It is about my being led, as cabinet secretary, by clinical opinion and clinical decision making—as I should be. The current difficulty is around the absence of clinical consensus, and I am grateful to Dr Cauchi for trying to help us to resolve that.

Johann Lamont Lab The Convener · Glasgow
link

Of course, but do you accept that part of the problem is that there are so few people who have the condition and that, although you are doing research and trying to establish the balance of probabilities and risk, there is no body of evidence, and if you wait for that body of evidence, those people may be denied the treatment that they need?

You talk about the balance of risks, but Professor Ottensmeier is explicit in saying that MRI is “not harmful to patients.” In the context of the risk that patients may be facing in not being given an MRI scan, do you accept that the general view that you have expressed about MRI bringing its own risk should be recognised and balanced against the experience of the patients?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Convener, you have encapsulated exactly what the clinicians, led by Dr Cauchi, are trying to resolve. I do not think that it is accurate to say that we are waiting for a body of research. We have a group that is actively engaged—in the absence of being able to secure UK-wide participation—in trying to resolve the issue at a Scottish level and reach a level of clinical consensus, which would address many of the issues that the petitioner and members of the committee are raising.

It is not about long-term research. It is about actively working to see whether it is possible to reach greater clinical consensus to guide the work, and the group will report soon, in June. Although there is, as you said, a clinician who believes that MRI scans do not carry risk, there are clinicians who would come forward and say that they do. That is the heart of the matter, and—

Johann Lamont Lab The Convener · Glasgow
link

It is a balance of risk that the patients say they are being denied, and if they lived in other parts of the country they would not be denied it. I am sure you can appreciate that, for them, this is not a theoretical argument about a balance of risks. It is about their sense that they are not having access to treatment on the basis of an argument, which is being propounded by Catherine Calderwood, that is not agreed with by everyone in the medical profession. I presume that not everyone agrees with it, or people with the condition would not be routinely given MRI scans in other parts of the United Kingdom.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

As I understand it from what Dr Calderwood has said and what I have read, in those circumstances, it is possible that there are areas in Scotland where people will move to the MRI scan rather than ultrasound, because there is a difference of view between clinicians about what is the most appropriate next step. I am absolutely not dealing with this as some theoretical debate. I am very conscious of the impact on individual patients. However, it is not for me as the cabinet secretary to overrule clinical experts in the area. Rather, I am grateful to Dr Cauchi for the work that he is doing. I look forward to his report and his recommendation on how he and his fellow clinicians should proceed.

Johann Lamont Lab The Convener · Glasgow
link

I appreciate that. Nobody is suggesting that you should overrule clinical evidence. The problem arises, and the petitioners repeat this point, because their condition is so rare. It is not that it is being overlooked, but it is not properly understood and there is not a body of evidence on it. Therefore, they feel that they are further punished, in the sense of the way in which the condition affects them, because there is not enough evidence on it.

I will bring in Maurice Corry at this point.

Maurice Corry Con West Scotland
link

There are also concerns that there is a large proportion of patients in Scotland whose risk status is unknown. In Mr Galloway’s report, he suggests that that is a consequence of many issues including some missing biopsies and metastatic spread of the disease being picked up too late. How do you answer the point that is made by the petitioner and Mr Galloway that ocular melanoma patients should be treated as being at high risk?

Dr Calderwood
link

The petitioner must be congratulated on bringing the issue of this rare condition to the committee and, in doing so, highlighting—as I said in answer to Mr MacDonald’s question—a condition that is so rare that most healthcare practitioners will not have heard of it, let alone come across it in a lifetime of practice.

On the convener’s point, the highlighting of the condition has led the two experts in Gartnavel hospital to go back and look at the evidence that we can get from the small number of cases in Scotland. I understand that an audit is being performed of the cases in Scotland—cases from the past, and looking forward. The audit aims to tie up the gaps in the data that you and the petitioner have pointed out, so that, where there is consensus, our guidelines could state that, for example, biopsies or certain tests needed to be done or a certain amount of follow-up was needed over particular periods of time, and the specialist centre would co-ordinate all of that. From the audit—I do not know its publication date—we will have more knowledge of the disease across Scotland in the people whom we have audited, and we will know where the gaps are.

As with many rare conditions, people obviously want to receive at least some of their treatments closer to home. For example, if someone lives far away from Gartnavel, they can have an ultrasound at their local hospital. Importantly, the audit will pick up whether those people are receiving the treatments that they should receive as if they were being treated in the specialist centre. We want to know whether we are giving the right treatment at specialist level whether that is delivered locally or at Gartnavel. We would not want a situation where patients who lived locally to Gartnavel or were able to travel there were getting a specialised service while others received services locally that did not tie up or co-ordinate with that.

I hope that the audit will highlight any gaps that exist with a view to improvements in relation to some of the data issues that you and the petitioner have highlighted.

Maurice Corry Con West Scotland
link

Will the report, which we hope will be published in June, also look at the determining of risk?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Yes. The updated guidelines that come from the work that is being done by clinicians and imaging experts—and which involves patients—will consider new evidence on genetic risk, which will inform the definition of high risk.

Maurice Corry Con West Scotland
link

Okay. Will the audit draw on the evidence from England? My very close friend’s son has this problem. Fortunately, it was caught by having an MRI scan and he is now in the six-month scan situation. He is a runner and he is leading a normal life, but he had to be medically discharged from the Army—from the special forces—so it is a tragic situation. The systems in Hereford and London picked it up and, so far, he is clear. Will the authors of the audit draw on the English results, too?

Dr Calderwood
link

I understand that they are reviewing all the evidence that is available. The plan is that, using that evidence and what we have from the small numbers in Scotland, we will pull together a consensus with much more standardised guidance for use around Scotland.

Maurice Corry Con West Scotland
link

I realise that, in England, things are better in some patches than in others—Liverpool and Southampton, for example, are extremely good, and I understand that Sheffield is coming up behind them. It is important that we look beyond the borders of Scotland.

10:15

David Torrance SNP Kirkcaldy
link

The petitioner has consistently made the point that ocular melanoma patients are referred only to ocular oncologists and should be seen by medical oncologists who have experience in liver disease. What is your opinion on that, cabinet secretary?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

My understanding is that, for the treatment of ocular melanoma, patients are seen by the ocular specialist, but if the cancer is detected as having spread to another organ, the oncology specialist in that organ will pick up on the treatment.

Johann Lamont Lab The Convener · Glasgow
link

The petitioner and Mr Galloway presented further arguments about the benefits of MRI as opposed to ultrasound. Access to MRI is often arranged in some places in England through a process of identifying and explaining the risks, but that option appears to have been closed down for patients in Scotland. Moreover, the option of joining clinical trials that offer new and promising therapies is denied to patients who have not had an MRI scan.

Apart from the point that was made about risk, which is obviously a matter of dispute, are there particular barriers or challenges about which the committee has not yet been informed that prevent ocular melanoma patients from accessing MRI scans?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

On the latter part of your question, my understanding is that there are no other factors in the way; it is about the absence of consensus on the balance of the risks. As I said, Dr Cauchi is trying to move us forward by looking at all the evidence that is available and considering imaging expertise, patient experience and so on. I do not know of additional barriers.

Johann Lamont Lab The Convener · Glasgow
link

If someone does not get an MRI scan, they cannot get into a clinical trial that might help their condition. You can see that, from the patient’s point of view, there is an incentive to have an MRI scan rather than ultrasound.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Yes, I understand what the petitioner is saying.

Johann Lamont Lab The Convener · Glasgow
link

Does that not change your view on what should happen?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

In truth, convener, given that I am a non-medically qualified cabinet secretary, it should not change my view. What should change my view is the work that is coming from clinicians and imaging experts, including work on patient experience, which I expect to receive in June. I think that the petitioner and other people would be reassured to know that it is not an unqualified politician who is changing their view and reorientating how clinical care is delivered—that is for the clinicians to do.

Johann Lamont Lab The Convener · Glasgow
link

It is clear to the petitioner that there are clinicians who think that the approach that is being taken is not the right one. It is not that there is no clinical evidence; it is about which clinical evidence you respond to, or the balance of the clinical evidence. Can I ask—

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Sorry, convener, but I must say that I do not believe that that is the case. I am not responding to one set of clinical views over another; I am looking for clinicians to find a way of reaching a degree of consensus that allows us to move forward and that is based on all available evidence. That is exactly what I am doing.

Johann Lamont Lab The Convener · Glasgow
link

Will you at least concede that the committee has been given evidence by some clinicians that the approach in Scotland is disadvantaging patients because they are not routinely getting MRI scans and that, to go back to David Torrance’s question, the fact that they go to an ocular oncologist rather than someone with broader expertise in the liver might mean that there are delays that cause problems?

I have another question. I appreciate the amount of time that you are giving to the petition. In the context of our consideration of the petition, there appears to be some difference of opinion about the merit of peer-reviewed evidence. The Scottish Government has indicated that a Scottish guidelines group will review articles. Has that been done? Are you aware of recent developments in that regard?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Dr Calderwood will respond initially to the latter part of your question, and I might add some comments. First, however, I say for the record that I absolutely appreciate the fact that the committee has heard from clinicians who believe that MRI scans should be the first port of call here. What I am saying is that other clinicians who are equally expert in the field would come before the committee and present the opposite view. That is the crux of the matter and the issue that we are trying to resolve.

I ask Dr Calderwood—

Johann Lamont Lab The Convener · Glasgow
link

Are you saying that there are clinicians who believe that people ought not to get MRI scans?

Johann Lamont Lab The Convener · Glasgow
link

You said that there are people who would present an absolutely opposite view. Which clinicians believe that there ought not to be an MRI scan for those who have the condition?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No, that is not what I am saying. The issue is that there are clinicians who believe that the risk that is posed by frequent MRI scans outweighs the benefits of having them, and there are others who take a different view.

Johann Lamont Lab The Convener · Glasgow
link

There are clinicians who have explicitly said that they believe that there is too much risk involved in giving people with this very rare condition an MRI scan. However, that is not the opposite of what Professor Ottensmeier is saying.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No. What I think I was trying to say to you was that you will get different views on the matter depending on the clinicians who give evidence to the committee. I do not think that that is disputed.

Johann Lamont Lab The Convener · Glasgow
link

With respect, cabinet secretary, you talked about clinicians presenting the “opposite view”. We have not received any evidence that puts forward an opposite view to the fact that these patients would benefit from an MRI scan for their condition. You are saying that there are people who are cautious with regard to the general implications of using MRI, but that does not address the specific issue of what is a very rare condition. We have not had clinicians saying the opposite of what Professor Ottensmeier has said. They might be reluctant to express a complete view on the matter but, although their general view is that there might be a risk attached to MRI, they are not saying that, as far as this condition is concerned, there is too much risk in having an MRI scan.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

No—the issue is not with there being an MRI scan, as you have said. I apologise if I used the wrong words, but there is a view among clinicians that the frequency of MRI scans that is required poses the risk that Dr Calderwood has outlined.

Johann Lamont Lab The Convener · Glasgow
link

With some conditions, there will always be some risk—indeed, you have referred to the balance of risk—but, to be clear, I say again that the committee has not received any evidence from clinicians that, as far as this condition is concerned, there is too much risk attached to a routine MRI scan. To be kind, I would say that the jury is out on the question, and you have said that you hope to have an answer to it by June.

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

What I am hoping to have by June is the report from Dr Cauchi’s group, if it can make progress on the matter.

I think that Dr Calderwood wanted to provide some information with regard to the other part of your question.

Dr Calderwood
link

On the Scottish guideline group that is looking at peer-reviewed evidence, I can provide the committee with a note to confirm whether that has been done.

Johann Lamont Lab The Convener · Glasgow
link

I do not know whether committee members have any more questions, but I have a final one. What do you expect to happen once Dr Cauchi reports? Will further time or a delay be required while standardised guidelines are developed? We might want to write to Dr Cauchi, asking him to give evidence, because, as the cabinet secretary has said and as we recognise, work is clearly being carried out on the matter. Indeed, we are not suggesting otherwise. What will be the next stage once he reports?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

The work that is being led by Dr Cauchi is about developing Scottish guidelines on liver surveillance, and his report will, I expect, include those revised and agreed—or introduced and agreed—guidelines. As I have said, they will consider new evidence on genetic risk to inform the definition of “high risk” and will advise on the best approaches for long-term follow-up, including continuing to offer local services along the lines that Dr Calderwood has mentioned, to ensure greater consistency of approach and access to those services.

Dr Calderwood
link

An advantage is that the two doctors who are involved are the specialists for Scotland, so they see every patient with the diagnosis as well as seeing them for regular follow-ups.

In contrast with some of the more common cancers, in respect of which there are lots of clinicians to communicate with, we will have guidance that has been produced by the group. The group involves the two specialists who see all patients and who make sure that there is an appropriate follow-up, which may be done locally. The specialists also follow up with the patients in person at Gartnavel on a regular basis. The implementation of, or any thought about, delay is removed because the two individuals are involved with every patient.

Johann Lamont Lab The Convener · Glasgow
link

If the report comes in June, will the guidelines be implemented from June?

Dr Calderwood
link

Yes, if the report has been written in the form of guidelines that need to be implemented. The specialists are writing the guidelines for themselves and not for other people. The guidelines will guide the scanning and so on that we are discussing. The people who are pulling together the evidence are the people who will implement the guidance.

Maurice Corry Con West Scotland
link

Dr Calderwood, have you seen the terms of reference that Dr Cauchi is proceeding with at the moment?

Dr Calderwood
link

I have not seen them as written terms of reference.

Maurice Corry Con West Scotland
link

You have not seen the terms of reference of what the report is, we hope, going to produce.

Dr Calderwood
link

I have seen a summary of them, which the cabinet secretary has read.

Maurice Corry Con West Scotland
link

The terms of reference are in black and white.

Dr Calderwood
link

I have not seen them written as formal terms of reference, but I have seen—

Maurice Corry Con West Scotland
link

Have you signed them off as being appropriate?

Dr Calderwood
link

I do not sign them off. That would not be appropriate, as I am not an expert in the field.

Maurice Corry Con West Scotland
link

Let us go back to the convener’s comment about the risk of MRI scans. Will there be a section in the report that addresses the scientific evidence of the risk element of multiple MRI scans? Will there be anything about that specifically?

Dr Calderwood
link

I understand that the evidence is being pulled together in order to give guidance on the routine management of imaging for follow-up for such patients.

Maurice Corry Con West Scotland
link

Do the terms of reference clearly refer to scientific evidence?

Dr Calderwood
link

We will need to gather what evidence there is in order to produce standardised guidance, as we would in any—

Maurice Corry Con West Scotland
link

So, you cannot say here today that that is actually clear in the terms of reference?

Dr Calderwood
link

Sorry—we are talking about two different things. I understand that guidance will be produced on the imaging that will be recommended in the follow-up for those patients. Beyond that, I do not know exactly what has been committed to, although I could ask to see the terms of reference.

Because there is such a small volume of scientific evidence, which relates to some rare conditions, there might have to be other ways of coming to a consensus. That might be done by having a shared decision-making conversation with the patient or achieving a consensus among experts rather than basing a decision purely on scientific evidence if it does not exist in any great volume.

I am now talking about detail that I have not discussed with the chair of the group. I can get the terms of reference for the committee, if that would be helpful.

Maurice Corry Con West Scotland
link

That would be good, because, as the convener says, there is a question about the scientific evidence. We have to be clear about where we are with MRIs. I visited a nuclear power station recently, and there are very clear guidelines on such visits, which are written by scientists. In this case, the users of science are the clinicians—are you with me?—and we need those scientists to give clear evidence. I am very surprised that you do not have a very clear view of the terms of reference in respect of that specific area.

Dr Calderwood
link

I would not routinely see such detail, Mr Corry. Given the situation that we are in, the scientific evidence must not come down very clearly on one side or another, or we would not be here.

Johann Lamont Lab The Convener · Glasgow
link

That is a circular argument that the petitioner would find difficult to break into.

I will finish with a quote from Iain Galloway’s submission. You may not be able to respond to it, but he makes this point, which I think is a powerful one that you may want to reflect on. He says:

“around 50% of all ocular melanoma patients have the disease return, and in those 90% or so in the liver. This same huge figure (which is considerably higher than many other cancers) of 50% will be the proportion of those whose risk is indeterminate whose cancer will return. That’s a significant proportion of our patients at risk who aren’t being appropriately scanned.”

We should also note that

“pharmaceutical companies and those sponsoring clinical trials will simply not permit ultrasound scans as sufficient evidence of disease spread (which is why they demand MRI) and we consequently deny this opportunity to our ‘indeterminate risk’ cohort too.”

Do you understand why that has become such a significant issue for the petitioner and those supporting her?

Jeane Freeman SNP Carrick, Cumnock and Doon Valley
link

Yes, I do. Our specialists at Gartnavel also understand that, which is why they have initiated and are leading work to address some of the issues that the petitioner raises.

Johann Lamont Lab The Convener · Glasgow
link

That brings us to the end of our consideration of the petition. It has been very useful to try to tease out the issues that have driven the petitioner to lodge the petition with the committee and those issues that arise from the evidence given by Mr Galloway.

We have said that we might like to hear from Dr Cauchi about the work that he is doing. As the cabinet secretary noted, the clinicians who are working in the field have a great deal more expertise than us. We would also want to hear from the petitioner and Mr Galloway, as well as from others who have an interest in responding to the evidence that we have heard.

Brian Whittle Con South Scotland
link

I agree. It is important that we at least link up the concerns raised by the petition to the current evidence gathering that is being carried out by the clinical experts, so that they are aware of those concerns.

Maurice Corry Con West Scotland
link

I would like to hear more about the scientific evidence of the risk of MRI, too.

Johann Lamont Lab The Convener · Glasgow
link

Okay. We can pursue that, too.

I thank the cabinet secretary for her evidence on the petition. To be charitable to us all, I suggest that we take a short break.

10:31 Meeting suspended.

10:40 On resuming—

  1. 09:00 Continued Petitions Petitions · 1
  2. 09:15 Continued Petitions Petitions · 68
  3. 09:45 Continued Petitions Petitions · 84
  4. 10:15 Continued Petitions Petitions · 52

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.